Press coverage about Trevena (NASDAQ:TRVN) has trended somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trevena earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 48.9276245881671 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of TRVN stock traded up $0.02 during trading hours on Friday, reaching $1.63. 1,416,898 shares of the company’s stock were exchanged, compared to its average volume of 1,140,047. Trevena has a 1 year low of $1.34 and a 1 year high of $2.88. The firm has a market capitalization of $122.49 million, a price-to-earnings ratio of -1.35 and a beta of -0.45. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.40 and a current ratio of 3.40.
Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The business had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $5.50 million. equities analysts forecast that Trevena will post -0.67 earnings per share for the current year.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.
See Also: Understanding Average Daily Trade Volume
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.